BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

High-wattage takeouts and commercial launches have revived interest in radiopharmaceuticals for cancer. The challenge for the new wave of candidates is to achieve enough differentiation to justify the logistical hurdles of manufacturing and delivering products...
BioCentury | Aug 4, 2017
Financial News

Follow-on Roundup: Actinium, Kamada, Tetraphase

...market hours. Investors also received five-year warrants to purchase 18.3 million shares at $1.05. Actinium's Iomab-B...
...Israel Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH), Watertown, Mass. Business: Cancer, Endocrine/Metabolic, Infectious Elizabeth S. Eaton BC8 inhaled alpha-1 antitrypsin (AAT) Iomab-B TP-434 Actinium...
BioCentury | Jul 28, 2017
Financial News

Follow-on roundup: Actinium, Kamada, Tetraphase

...purchase 18.3 million shares at $1.05. Actinium fell $0.30 (31%) to $0.67 on Friday. Actinium's Iomab-B...
BioCentury | Jul 11, 2016
Clinical News

BC8-I-131: Phase III started

...Actinium began the open-label, Phase III SIERRA trial to compare Iomab-B vs. physician’s choice of chemotherapy...
...with relapsed or refractory AML. Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), New York, N.Y. Product: BC8-I-131 , Iomab-B...
BioCentury | Jun 9, 2016
Distillery Therapeutics

Therapeutics: CD45

...non-human primate models of HSCT (see "Killing HSCs Softly," page 17). Actinium Pharmaceuticals Inc. has Iomab-B...
BioCentury | Jun 9, 2016
Translation in Brief

Killing HSCs softly

...and organs, have restricted use of the procedure. Actinium Pharmaceuticals Inc. (NYSE-M:ATNM) has BC8-I-131 ( Iomab-B...
BioCentury | Jun 30, 2014
Finance

Highlights of weekly biotech stock moves

...company's Actimab-A is in Phase I/II testing to treat acute myelogenous leukemia (AML), while its Iomab-B...
BioCentury | Jun 25, 2014
Financial News

Actinium, Heron planning follow-ons

...lintuzumab (HuM195), is in Phase I/II testing to treat acute myelogenous leukemia (AML). The company's Iomab-B...
BioCentury | Dec 27, 2012
Financial News

Actinium raises $5.1M ahead of reverse-merger

...Phase I/II testing for acute myelogenous leukemia (AML), with data expected in 2Q13. The company's Iomab-B...
BioCentury | Dec 10, 2012
Clinical News

Iomab-B: Phase II data

...trial in 14 patients <50 years old with advanced AML or high-risk MDS showed that Iomab-B...
...led to a PFS rate of 36% at a median follow-up of 87 months post-HCT. Iomab-B...
...in 7 patients. There have been 7 deaths, with 5 patients relapsing 0.9-45 months post-HCT. Iomab-B...
Items per page:
1 - 10 of 11